Fate Therapeutics (FATE) Non-Current Deffered Revenue (2012 - 2022)

Fate Therapeutics has reported Non-Current Deffered Revenue for 11 years, with the latest figure at $12.4 million in Q3 2022.

• For the quarter ending Q3 2022, Non-Current Deffered Revenue fell 61.9% year-over-year to $12.4 million; the trailing twelve-month figure through Sep 2022 stood at $12.4 million (down 61.9% YoY), and the FY2021 full-year result was $27.1 million, down 41.06% from the prior year.
• Non-Current Deffered Revenue for Q3 2022 stood at $12.4 million, down from $17.7 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $54.7 million in Q2 2020, with the low at $1.3 million in Q1 2018.
• Historically, Non-Current Deffered Revenue has averaged $20.0 million across 5 years, with a median of $12.4 million in 2022.
• Annual changes were most pronounced in 2021 — Non-Current Deffered Revenue jumped 1277.24% — and 2022, when it tumbled 61.9%.
• Fate Therapeutics' Non-Current Deffered Revenue stood at $7.5 million in 2018, then slumped by 49.67% to $3.8 million in 2019, then jumped by 1119.1% to $46.0 million in 2020, then tumbled by 41.06% to $27.1 million in 2021, then slumped by 54.26% to $12.4 million in 2022.
• The last three Non-Current Deffered Revenue figures came in at $12.4 million (Q3 2022), $17.7 million (Q2 2022), and $22.5 million (Q1 2022), per Business Quant data.